Why is Vanda Pharmaceuticals stock surging today?

Vanda Pharmaceuticals (VNDA) shares dropped 6.2% after hours as its Phase III trial for VQW-765 failed to meet the primary endpoint in treating acute anxiety in adults with social anxiety disorder. The study was a multicenter, randomized, double-blind, placebo-controlled trial conducted at 30 U.S. sites.

Vanda Pharmaceuticals' phase 3 trial for VQW-765, an investigational treatment for social anxiety disorder, missed its primary endpoint. The study showed no significant difference in distress levels between participants receiving VQW-765 and those receiving a placebo. The company is evaluating the data, and the clinical program is currently on hold.

Vanda Pharmaceuticals halted development of VQW-765, a social anxiety drug licensed from Novartis, after it failed to show significant benefit in a late-stage study. The Phase 3 trial, focused on female participants, showed no distress reduction versus placebo. Vanda will analyze the full dataset before deciding next steps. Oppenheimer analysts noted this was a clean miss but do not expect it to significantly impact their estimates for Vanda.

Vanda Pharmaceuticals (VNDA) shares fell 2% premarket after its Phase III trial for anxiety drug VQW-765 failed to meet primary and key secondary endpoints. The company paused the program for further analysis, confirming the drug's safety. VNDA's P/S ratio is 1.16, below historical and industry medians, reflecting market skepticism. Insider selling totaled $2.8M, with mixed institutional sentiment.

Vanda Pharmaceuticals (VNDA) announced its Phase III trial for VQW-765 failed to meet primary endpoints in treating acute anxiety. The company's P/S ratio is 1.21, below its historical median, and its GF Score is 66. Insider sales totaled $2.8M over the past year, with no purchases. VNDA's market cap is $255M, and it remains unprofitable.

Vanda Pharmaceuticals (VNDA) shares dropped 6.2% after its anxiety drug VQW-765 failed to meet the primary endpoint in a Phase III trial. The study did not show statistical significance in reducing distress levels in female participants with social anxiety disorder. The company plans to analyze the full dataset before deciding on next steps. VQW-765 was licensed from Novartis and is being developed for psychiatric disorders.